47046.1 IP-LS

Résumé

Towards automated manufacturing of clinical grade CAR T-cells for cancer treatment

Textes supplémentaires

Abstract

Widespread use of cancer therapies based on CAR T-cells is hampered by the complexity of their manufacturing. We developed a concept of fully automated platform and want to bring our device to a prototype stage. We will demonstrate biological relevance to find partnerships for POC applications.

Participants

Matthias Lutolf

Kontaktperson

matthias.lutolf@epfl.ch

EPFL SV IBI LSCB Matthias Lutolf Station 15, Bâtiment Al 1109 1015 Lausanne VD CH

Détails du projet

Office de recherche: INNOSUISSE
Statut du projet: Abgeschlossen
Type de projet: Forschungsprojekt
Date de début: 2020-12-31
Date de fin: 2022-09-30
Coûts totaux approuvés: CHF 680362.56
Section: 60 Life Sciences
Domaine politique NABS: Industrielle Produktivität und Technologie

Disciplines de recherche

T490 Biotechnology 100.0%